Cancer stemness; Immunoevasion; Mesenchymal phenotype; PD-L1
Abstract :
[en] Recent advances in tumor immunology, fostered by dramatic outcomes with cancer immunotherapy, have opened new scenarios in cancer metastasis. The cancer stemness/mesenchymal phenotype and an excess of immune suppressive signals are emerging as Intertwined aspects of human tumors. This review examines recent studies that explored the mechanistic links between cancer cell stemness and immunoevasion, and the evidence points to these key events in cancer metastasis as two sides of the same coin. This review also covers the mechanisms involved in tumor expression of programmed cell death ligand 1 (PD-L1), a major factor exploited by human neoplasias to suppress immune control. We highlight the convergence of mesenchymal traits and PD-L1 expression and examine the functions of this immune inhibitory molecule, which confers cancer cell resistance and aggressiveness.
Disciplines :
Oncology
Author, co-author :
Romano, Simona
Tufano, Martina
D'arrigo, Paolo ; Université de Liège - ULiège > I3-Virology and Immunology
Vigorito, Vincenza
Russo, Salvatore
Romano, Maria Fiammetta
Language :
English
Title :
Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis.
Ahmed, N., Escalona, R., Leung, D., Chan, E., Kannourakis, G., Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin. Cancer Biol. 53 (2018), 265–281, 10.1016/j.semcancer.2018.10.002.
Wang, H., Unternaehrer, J.J., Epithelial-mesenchymal transition and cancer stem cells: at the crossroads of differentiation and dedifferentiation. Dev. Dyn. 248 (2019), 10–20, 10.1002/dvdy.24678.
Gallacher, L., Li, L., Baroja, M.L., Majumdar, A., Chadwick, K., Rouleau, A., et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 22 (2004), 448–456, 10.1634/stemcells.22-4-448.
Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24 (2006), 221–229, 10.1634/stemcells.2005-0188.
Schatton, T., Frank, M.H., Antitumor immunity and cancer stem cells. Ann. N. Y. Acad. Sci. 1176 (2009), 154–169, 10.1111/j.1749-6632.2009.04568.x.
Schatton, T., Schütte, U., Frank, N.Y., Zhan, Q., Hoerning, A., Robles, S.C., et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 15:70 (2010), 697–708, 10.1158/0008-5472.CAN-09-1592.
Chang, C.J., Yen, M.L., Chen, Y.C., Chien, C.C., Huang, H.I., Bai, C.H., et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24 (2006), 2466–2477, 10.1634/stemcells.2006-0071.
Romieu-Mourez, R., François, M., Boivin, M.N., Stagg, J., Galipeau, J., Regulation of MHC class II expression and antigen processing in murine and humanmesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J. Immunol. 179 (2007), 1549–1558, 10.4049/jimmunol.179.3.1549.
Becker, J.C., Brabletz, T., Czerny, C., Termeer, C., Bröcker, E.B., Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int. Immunol. 5 (1993), 1501–1508, 10.1093/intimm/5.12.1501.
Di Tomaso, T., Mazzoleni, S., Wang, E., Sovena, G., Clavenna, D., Franzin, A., et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 1:16 (2010), 800–813, 10.1158/1078-0432.CCR-09-2730.
Barr, J., Wei, J., Kong, L.Y., Wang, Y., Wu, A., Sharma, A.K., et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 9 (2010), 67–78, 10.1158/1535-7163.MCT-09-0734.
Huynh, J., Etemadi, N., Hollande, F., Ernst, M., Buchert, M., The JAK/STAT3 axis: a comprehensive drug target for solid malignancies. Semin. Cancer Biol. 45 (2017), 13–22, 10.1016/j.semcancer.2017.06.001.
Lee, Y., Shin, J.H., Longmire, M., Wang, H., Kohrt, H.E., Chang, H.Y., et al. CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin. Cancer Res. 22 (2016), 3571–3581, 10.1158/1078-0432.CCR-15-2665.
Ozaki, M., Nishino, M., Hegab, A.E., Hamamoto, J., Kagawa, S., Arai, D., et al. Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. J. Cancer 8 (2017), 1774–1785, 10.7150/jca.19732.
Castagnoli, L., Cancila, V., Cordoba-Romero, S.L., Faraci, S., Talarico, G., Belmonte, B., et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene, 2019, 10.1038/s41388-019-0700-2.
Kerdidani, D., Chouvardas, P., Arjo, A.R., Giopanou, I., Ntaliarda, G., Guo, Y.A., et al. Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. Nat. Commun., 10, 2019, 1405, 10.1038/s41467-019-09370-z.
Su, W., Han, H.H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell(19), 2019, S1535–6108, 10.1016/j.ccell.2019.06.009 pii:30300-9.
Janse van Rensburg, H.J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., et al. The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res. 78 (2018), 1457–1470, 10.1158/0008-5472.CAN-17-3139.
Chen, T., Du, J., Lu, G., Cell growth arrest and apoptosis induced by Oct4 or Nanog knockdown in mouse embryonic stem cells: a possible role of Trp53. Mol. Biol. Rep. 39 (2012), 1855–1861, 10.1007/s11033-011-0928-6.
Mamun, M.A., Mannoor, K., Cao, J., Qadri, F., Song, X., SOX2 in cancer stemness: tumor malignancy and therapeutic potentials. J. Mol. Cell Biol., 2018, 10.1093/jmcb/mjy080.
Volonté, A., Di Tomaso, T., Spinelli, M., Todaro, M., Sanvito, F., Albarello, L., et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J. Immunol. 192 (2014), 523–532, 10.4049/jimmunol.1301342.
Martinez-Outschoorn, U.E., Peiris-Pagés, M., Pestell, R.G., Sotgia, F., Lisanti, M.P., Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol. 14 (2017), 11–31, 10.1038/nrclinonc.2016.60.
Shibue, T., Weinberg, R.A., EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14 (2017), 611–629, 10.1038/nrclinonc.2017.44.
De Craene, B., Berx, G., Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13 (2013), 97–110, 10.1038/nrc3447.
Muqbil, I., Wu, J., Aboukameel, A., Mohammad, R.M., Azmi, A.S., Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?. Semin. Cancer Biol. 27 (2014), 39–45, 10.1016/j.semcancer.2014.06.003.
Simeone, P., Trerotola, M., Franck, J., Cardon, T., Marchisio, M., Fournier, I., et al. The multiverse nature of epithelial to mesenchymal transition. Semin. Cancer Biol., 16(November), 2018, 10.1016/j.semcancer.2018.11.004 pii: S1044-579X(18)30086-5.
Moustakas, A., Heldin, C.H., Induction of epithelial-mesenchymal transition by transforming growth factor β. Semin. Cancer Biol. 22 (2012), 446–454, 10.1016/j.semcancer.2012.04.002.
Lou, Y., Diao, L., Cuentas, E.R., Denning, W.L., Chen, L., Fan, Y.H., et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22 (2016), 3630–3642, 10.1158/1078-0432.CCR-15-1434.
Cui, T.X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R., Roh, M.H., et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39 (2013), 611–621, 10.1016/j.immuni.2013.08.025.
Lu, H., Clauser, K.R., Tam, W.L., Fröse, J., Ye, X., Eaton, E.N., et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol. 16 (2014), 1105–1117, 10.1038/ncb3041.
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70 (2010), 6945–6956, 10.1158/0008-5472.CAN-10-0785.
Ye, J., Wu, D., Wu, P., Chen, Z., Huang, J., The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol. 35 (2014), 3945–3951, 10.1007/s13277-013-1561-x.
Fisher, D.T., Appenheimer, M.M., Evans, S.S., The two faces of IL-6 in the tumor microenvironment. Semin. Immunol. 26 (2014), 38–47, 10.1016/j.smim.2014.01.008.
Kim, S.Y., Kang, J.W., Song, X., Kim, B.K., Yoo, Y.D., Kwon, Y.T., et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell. Signal. 25 (2013), 961–969, 10.1016/j.cellsig.2013.01.007.
Rőszer, T., Understanding the misterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm., 2015, 1–16, 10.1155/2015/816460.
Grimaldi, E., Carandente, P., Scopacasa, F., Romano, M.F., Pellegrino, M., Bisogni, R., et al. Evaluation of the monocyte counting by two automated haematology analysers compared with flow cytometry. Clin. Lab. Haematol. 25 (2005), 91–97, 10.1111/j.1365-2257.2005.00676.x.
Plaks, V., Kong, N., Werb, Z., The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell Stem Cell 16 (2015), 225–238, 10.1016/j.stem.2015.02.015.
Fu, X.T., Dai, Z., Song, K., Zhang, Z.J., Zhou, Z.J., Zhou, S.L., et al. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int. J. Oncol. 46 (2015), 587–596, 10.3892/ijo.2014.2761.
Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25 (2014), 605–620, 10.1016/j.ccr.2014.03.021.
Zhang, B., Yin, C., Li, H., Shi, L., Liu, N., Sun, Y., et al. Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK3β/Snail signalling pathway. Eur. J. Cancer 49 (2013), 3900–3913, 10.1016/j.ejca.2013.07.146.
Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., van Roy, F., et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26 (2007), 7445–7456, 10.1038/sj.onc.1210546.
Zhou, C., Nitschke, A.M., Xiong, W., Zhang, Q., Tang, Y., Bloch, M., et al. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res., 10, 2008, R105, 10.1186/bcr2210.
Liu, C.Y., Xu, J.Y., Shi, X.Y., Huang, W., Ruan, T.Y., Xie, P., et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab. Invest. 93 (2013), 844–854, 10.1038/labinvest.2013.69.
Asuthkar, S., Nalla, A.K., Gondi, C.S., Dinh, D.H., Gujrati, M., Mohanam, S., et al. Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT. Neuro Oncol. 13 (2011), 1059–1073, 10.1093/neuonc/nor109.
Junttila, M.R., de Sauvage, F.J., Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 501 (2013), 346–354, 10.1038/nature12626.
Sánchez-Martín, L., Estecha, A., Samaniego, R., Sánchez-Ramón, S., Vega, M., Sánchez-Mateos, P., The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117 (2011), 88–97, 10.1182/blood-2009-12-258186.
Sica, A., Mantovani, A., Allavena, P., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444, 10.1038/nature07205.
Zanotto, M., Ricciardi, M., Malpeli, G., Bassi, G., Perbellini, O., Chilosi, M., et al. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br. J. Cancer 112 (2015), 1067–1075, 10.1038/bjc.2015.29.
Huergo-Zapico, L., Parodi, M., Cantoni, C., Lavarello, C., Fernández-Martínez, J.L., Petretto, A., et al. NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell lines. Cancer Res. 78 (2018), 3913–3925, 10.1158/0008-5472.CAN-17-1891.
Astudillo, A., López-Soto, A., Huergo-Zapico, L., Galván, J.A., Rodrigo, L., de Herreros, A.G., et al. Epithelial–mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J. Immunol. 190 (2013), 4408–4419, 10.4049/jimmunol.1202950.
Chockley, P.J., Chen, J., Chen, G., Beer, D.G., Standiford, T.J., Keshamouni, V.G., Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer. J. Clin. Invest. 128 (2018), 1384–1396, 10.1172/JCI97611.
D'Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., et al. Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules. Curr. Med. Chem., 2018, 10.2174/0929867325666181106114421.
Sokolov, A., Paull, E.O., Stuart, J.M., One-class detection of cell states in tumor subtypes. Pac. Symp. Biocomput. 21 (2016), 405–416, 10.1142/9789814749411_0037.
Malta, T.M., Sokolov, A., Gentles, A.J., Burzykowski, T., Poisson, L., Weinstein, J.N., et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173 (2018), 338–354, 10.1016/j.cell.2018.03.034 e15.
Garcia-Diaz, A., Shin, D.S., Moreno, B.H., Saco, J., Escuin-Ordinas, H., Rodriguez, G.A., et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19 (2017), 1189–1201, 10.1016/j.celrep.2017.04.031.
Jin, Y.H., Hou, W., Kang, H.S., Koh, C.S., Kim, B.S., The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus. J. Virol. 87 (2013), 11538–11551, 10.1128/JVI.01967-13.
Xu, Y., Poggio, M., Jin, H.Y., Shi, Z., Forester, C.M., Wang, Y., et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat. Med. 25 (2019), 301–311, 10.1038/s41591-018-0321-2.
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat. Med. 24 (2018), 1877–1886, 10.1038/s41591-018-0217-1.
Deng, Y., Wang, F., Hughes, T., Yu, J., FOXOs in cancer immunity: knowns and unknowns. Semin. Cancer Biol. 50 (2018), 53–64, 10.1016/j.semcancer.2018.01.005.
George, J., Saito, M., Tsuta, K., Iwakawa, R., Shaishi, K., Scheel, A.H., et al. Genomic amplification of CD274 (PD-L1) in small-cell lung cancer. Clin. Cancer Res. 23 (2017), 1220–1226, 10.1158/1078-0432.CCR-16-1069.
Straub, M., Drecoll, E., Pfarr, N., Weichert, W., Langer, R., Hapfelmeier, A., et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget 7 (2016), 12024–12034, 10.18632/oncotarget.7593.
Howitt, B.E., Sun, H.H., Roemer, M.G., Kelley, A., Chapuy, B., Aviki, E., et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol. 2 (2016), 518–522, 10.1001/jamaoncol.2015.6326.
Budczies, J., Denkert, C., Győrffy, B., Schirmacher, P., Stenzinger, A., Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. BMC Med. Genomics, 10, 2017, 74, 10.1186/s12920-017-0308-8.
Barrett, M.T., Anderson, K.S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H.E., Klassen, C.L., et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6 (2015), 26483–26493, 10.18632/oncotarget.4494.
Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209, 10.1038/nature13480.
Steidl, C., Shah, S.P., Woolcock, B.W., Rui, L., Kawahara, M., Farinha, P., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471 (2011), 377–381, 10.1038/nature09754.
Paessler, M., Marzec, M., Zhang, Q., Goradia, A., Raghunath, P.N., Liu, X., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). PNAS 105 (2008), 20852–20857, 10.1073/pnas.0810958105.
Wang, Y.F., Liu, F., Sherwin, S., Farrelly, M., Yan, X.G., Croft, A., et al. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells. J. Invest. Dermatol. 138 (2018), 922–932, 10.1016/j.jid.2017.11.009.
Lu, C., Paschall, A.V., Shi, H., Savage, N., Waller, J.L., Sabbatini, M.E., et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J. Natl. Cancer Inst., 109, 2017, djw283, 10.1093/jnci/djw283.
Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y., Wang, T., et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat. Commun., 7, 2016, 11406, 10.1038/ncomms11406.
Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell. Signal. 27 (2015), 443–452, 10.1016/j.cellsig.2014.12.003.
Zhao, L., Yu, H., Yi, S., Peng, X., Su, P., Xiao, Z., et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 7 (2016), 45370–45384, 10.18632/oncotarget.9659.
Duan, Y., Zhang, Y., Xiang, C., Wang, Y., Liu, C., Zhang, Y., PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. Oncotarget 8 (2017), 101535–101544, 10.18632/oncotarget.21328.
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534 (2016), 402–406, 10.1038/nature18294.
Parsa, A.T., Waldron, J.S., Panner, A., Crane, C.A., Parney, I.F., Barry, J.J., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13 (2007), 84–88, 10.1038/nm1517.
Crane, C.A., Panner, A., Murray, J.C., Wilson, S.P., Xu, H., Chen, L., et al. PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 28 (2009), 306–312, 10.1038/onc.2008.384.
Wang, S., Xu, L., Che, X., Li, C., Xu, L., Hou, K., et al. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer. FEBS Lett. 59 (2018), 621–630, 10.1002/1873-3468.12985.
Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., Nakata, M., PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol. Immunother. 66 (2017), 865–876, 10.1007/s00262-017-1986-y.
Hsu, J.M., Li, C.W., Lai, Y.J., Hung, M.C., Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 78 (2018), 6349–6353, 10.1158/0008-5472.CAN-18-1892.
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun., 7, 2016, 12632, 10.1038/ncomms12632.
Chen, M., Sharma, A., Lin, Y., Wu, Y., He, Q., Gu, Y., et al. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1 (PD-L1) production and transport in colon cancer stem cells. BMC Cancer, 19, 2019, 153, 10.1186/s12885-019-5364-3.
Cha, J.H., Yang, W.H., Xia, W., Wei, Y., Chan, L.C., Lim, S.O., et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol. Cell 71 (2018), 606–620, 10.1016/j.molcel.2018.07.030 e7.
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N.T., et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553 (2018), 91–95, 10.1038/nature25015.
D'Arrigo, P., Russo, M., Rea, A., Tufano, M., Guadagno, E., Del Basso De Caro, M.L., et al. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget 8 (2017), 68291–68304, 10.18632/oncotarget.19309.
Cuboni, S., Gaali, S., Kirschner, A., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A.S., Draenert, R., Binder, E.B., Almeida, O.F., Rühter, G., Uhr, M., Schmidt, M.V., Touma, C., Bracher, A., Hausch, F., Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat. Chem. Biol. 11 (2015), 33–37, 10.1038/nchembio.1699.
Chen, R.Q., Liu, F., Qiu, X.Y., Chen, X.Q., The prognostic and therapeutic value of PD-L1 in glioma. Front. Pharmacol., 9, 2019, 1503, 10.3389/fphar.2018.01503.
Azuma, T., Yao, S., Zhu, G., Flies, A.S., Flies, S.J., Chen, L., B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111 (2008), 3635–3643, 10.1182/blood-2007-11-123141.
Ibañez-Vea, M., Gato-Cañas, M., Zuazo, M., Arasanz, H., Lorenzo, L., Fernandez-Hinojal, G., et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 20 (2017), 1818–1829, 10.1016/j.celrep.2017.07.075.
Chen, S., Liu, S., Yuan, W., Wang, H., Chen, K., Li, D., et al. PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget 8 (2017), 99901–99912, 10.18632/oncotarget.21914.
Zhao, L., Li, C., Liu, F., Zhao, Y., Liu, J., Hua, Y., et al. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco. Ther. 10 (2017), 2115–2126, 10.2147/OTT.S130481.
Zhang, Q., Zhang, Y., Chen, Y., Qian, J., Zhang, X., Yu, K.A., Novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases, and improves antitumor immunity in preclinical models of lung cancer. Clin. Cancer Res., 2019, 10.1158/1078-0432.CCR-18-2548.
Xue, S., Hu, M., Li, P., Ma, J., Xie, L., Teng, F., et al. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget 8 (2017), 49702–49712, 10.18632/oncotarget.17922.
Clark, C.A., Gupta, H.B., Sareddy, G., Pandeswara, S., Lao, S., Yuan, B., et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76 (2016), 6964–6974, 10.1158/0008-5472.CAN-16-0258.
Kraft, S., Fernandez-Figueras, M.T., Richarz, N.A., Flaherty, K.T., Hoang, M.P., PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. J. Am. Acad. Dermatol. 77 (2017), 534–542, 10.1016/j.jaad.2017.05.007.
Zhang, C., Jiang, F., Su, C., Xie, P., Xu, L., Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway. J. Cell. Biochem., 2019, 10.1002/jcb.28444.
Kim, S., Koh, J., Kim, M.Y., Kwon, D., Go, H., Kim, Y.A., et al. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum. Pathol. 58 (2016), 7–14, 10.1016/j.humpath.2016.07.007.
Tsutsumi, S., Saeki, H., Nakashima, Y., Ito, S., Oki, E., Morita, M., et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci. 108 (2017), 1119–1127, 10.1111/cas.13237.
Chen, L., Gibbons, D.L., Goswami, S., Cortez, M.A., Ahn, Y.H., Byers, L.A., et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun., 5, 2014, 5241, 10.1038/ncomms6241.
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol. Cancer, 14, 2015, 149, 10.1186/s12943-015-0421-2.
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., et al. MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer Res. 78 (2018), 205–215, 10.1158/0008-5472.CAN-17-1636.
Gupta, H.B., Clark, C.A., Yuan, B., Sareddy, G., Pandeswara, S., Padron, A.S., et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct. Target. Ther., 1, 2016, 10.1038/sigtrans.2016.30 pii: 16030.
Almozyan, S., Colak, D., Mansour, F., Alaiya, A., Al-Harazi, O., Qattan, A., et al. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Int. J. Cancer 141 (2017), 1402–1412, 10.1002/ijc.30834.
Wang, H., Deng, J., Ren, H.Y., Jia, P., Zhang, W., Li, M.Q., Li, S.W., Zhou, Q.H., STAT3 influences the characteristics of stem cells in cervical carcinoma. Oncol. Lett. 14 (2017), 2131–2136, 10.3892/ol.2017.6454.
Tamai, K., Nakamura, M., Mizuma, M., Mochizuki, M., Yokoyama, M., Endo, H., et al. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci. 105 (2014), 667–674, 10.1111/cas.12406.
Jinesh, G.G., Manyam, G.C., Mmeje, C.O., Baggerly, K.A., Kamat, A.M., Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci. Rep., 7, 2017, 9602, 10.1038/s41598-017-08796-z.